Boc-Phe-Ser-Arg-AMC是一种在被蛋白酶切割后可释放高荧光强度AMC(Ex/Em: 355nm/460nm)的荧光底物,具有被凝血因子XIa优先水解的特点,并被广泛应用于胰蛋白酶、类胰蛋白酶及激肽释放酶等酶活性的检测。
Cas No.:73554-90-2
Sample solution is provided at 25 µL, 10mM.
Boc-Phe-Ser-Arg-AMC is a fluorescent substrate that, upon cleavage by proteases, releases highly fluorescent AMC (Ex/Em: 355 nm/460 nm). Boc-Phe-Ser-Arg-AMC is characterized by its preferential hydrolysis by coagulation factor XIa and is widely used for detecting the activities of enzymes such as trypsin, tryptase, and kallikrein[1,2,3]. Boc-Phe-Ser-Arg-AMC is also highly sensitive to proteases in yeast mitochondrial matrix and trypsin in rat mast cells. After the Arg-AMC peptide bond is cleaved by proteases, AMC is released, and the increase in fluorescence intensity is proportional to the enzyme activity[4,5,6].
References:
[1] KALE S S, BERGERON-BRLEK M, WU Y, et al. Thiol-to-amine cyclization reaction enables screening of large libraries of macrocyclic compounds and the generation of sub-kilodalton ligands[J]. Science Advances, 2019, 5(8): eaaw2851.
[2] GONG Z, DAI S, JIANG X, et al. Variants in KLK11, affecting signal peptide cleavage of kallikrein-related peptidase 11, cause an autosomal-dominant cornification disorder[J]. British Journal of Dermatology, 2023, 188(1): 100-111.
[3] KOMATSU N, SAIJOH K, KUK C, et al. Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy[J]. British Journal of Dermatology, 2007, 156(5): 875-883.
[4] BRAGANZA V J, SIMMONS W H. Tryptase from rat skin: purification and properties[J]. Biochemistry, 1991, 30(20): 4997-5007.
[5] YASUHARA T, OHASHI A. New chelator-sensitive proteases in matrix of yeast mitochondria[J]. Biochemical and Biophysical Research Communications, 1987, 144(1): 277-283.
[6] ROEDL D, TRAIDL-HOFFMANN C, RING J, et al. Serine protease inhibitor lymphoepithelial Kazal type-related inhibitor tends to be decreased in atopic dermatitis. 2009.
Boc-Phe-Ser-Arg-AMC是一种在被蛋白酶切割后可释放高荧光强度AMC(Ex/Em: 355nm/460nm)的荧光底物,具有被凝血因子XIa优先水解的特点,并被广泛应用于胰蛋白酶、类胰蛋白酶及激肽释放酶等酶活性的检测[1,2,3]。Boc-Phe-Ser-Arg-AMC对酵母线粒体基质中的蛋白酶以及大鼠肥大细胞中的胰蛋白酶也高度敏感,被蛋白酶切割Arg-AMC肽键后释放AMC,其荧光强度的增加与酶活性成正比[4,5,6]。
使用Boc-Phe-Ser-Arg-AMC测定角质层样品中类胰蛋白酶的活性[1]:
(1)取0.5mg冻干的角质层样品与500μL测定缓冲液(50mM Tris, 1M NaCl, 10mM EDTA, pH 8.5)混合,在37℃摇床上孵育1h,后在4℃下以13000×g离心10min。
(2)获取上清液进行蛋白酶活性测定,使用Boc-Phe-Ser-Arg-AMC作为测定类胰蛋白酶活性的底物。
(3)将100μL上清样品与100μL含有0.75mM Boc-Phe-Ser-Arg-AMC的测定缓冲液混合,在37℃下孵育5h,并每小时测量一次活性。
(4)使用多功能微孔板检测仪在Ex/Em为355nm/460nm下检测释放的AMC,并使用AMC标准品进行校准。
使用Boc-Phe-Ser-Arg-AMC测定Kallikrein-related peptidase 6(KLK6)活性[2]:
(1)向384黑孔板的每个孔中加入5μL抑制剂(使用1:2或1:3稀释,达到不同的最终测定浓度)或DMSO对照(最终测定浓度2%)。
(2)再加入5μL溶解于反应缓冲液(50mM Tris, 150mM NaCl, 1mM EDTA, 0.05% Tween-20, pH 7.5)的KLK6(最终测定浓度5nM),于室温下孵育30min。
(3)在开始动力学测量荧光强度(Ex, 350 ± 15nm; Em, 440 ± 20nm; 每60s一次,持续30min)之前,立即向每孔中加入10μL溶于反应缓冲液的底物Boc-Phe-Ser-Arg-AMC(最终测定浓度为20μM)。
(4)使用GraphPad Prism计算测得信号的斜率,将其相对于DMSO对照(100%活性)进行标准化,然后用于生成剂量反应曲线。
References:
[1] GONG Z, DAI S, JIANG X, et al. Variants in KLK11, affecting signal peptide cleavage of kallikrein-related peptidase 11, cause an autosomal-dominant cornification disorder[J]. British Journal of Dermatology, 2023, 188(1): 100-111.
[2] DE VITA E, SCHÜLER P, LOVELL S, et al. Depsipeptides featuring a neutral P1 are potent inhibitors of kallikrein-related peptidase 6 with on-target cellular activity[J]. Journal of Medicinal Chemistry, 2018, 61(19): 8859-8874.
| Cas No. | 73554-90-2 | SDF | |
| 别名 | 叔丁氧羰基-苯丙氨酰-丝氨酰-精氨酸-7-氨基-4-甲基香豆素 | ||
| 分子式 | C33H43N7O8 | 分子量 | 665.75 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5021 mL | 7.5103 mL | 15.0207 mL |
| 5 mM | 300.4 μL | 1.5021 mL | 3.0041 mL |
| 10 mM | 150.2 μL | 751 μL | 1.5021 mL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >90.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
















